We are live on ! Find out more
GHDX

Genomic Health, Inc.
GHDX

Delisted

GHDX was delisted on the 7th of November, 2019.

134 hedge funds and large institutions have $870M invested in Genomic Health, Inc. in 2016 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 53 increasing their positions, 42 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 10

26% more repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 42

13% more capital invested

Capital invested by funds: $772M → $870M (+$97.6M)

3% more funds holding

Funds holding: 130134 (+4)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

100% less call options, than puts

Call options by funds: $1K | Put options by funds: $220K

Holders
134
Holders Change
+4
Holders Change %
+3.08%
% of All Funds
3.58%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
14
Increased
53
Reduced
42
Closed
10
Calls
$1K
Puts
$220K
Net Calls
-$219K
Net Calls Change
+$148K
Name Holding Trade Value Shares
Change
Change in
Stake
Two Sigma Advisers
26
Two Sigma Advisers
New York
$4.52M +$1.56M +55,999 +56%
Mitsubishi UFJ Trust & Banking
27
Mitsubishi UFJ Trust & Banking
Japan
$4.41M +$78.6K +2,820 +2%
Norges Bank
28
Norges Bank
Norway
$4.27M +$1.97M +70,576 +84%
BG
29
BlackRock Group
United Kingdom
$4.18M -$1.33M -47,673 -25%
CCMH
30
Cornerstone Capital Management Holdings
New York
$4.03M +$206K +7,400 +6%
OC
31
Oppenheimer & Co
New York
$4.01M -$83.6K -3,000 -2%
MFAM
32
Motley Fool Asset Management
Virginia
$3.82M
Skandinaviska Enskilda Banken (SEB)
33
Skandinaviska Enskilda Banken (SEB)
Sweden
$3.73M +$1.86M +66,900 +108%
MFWM
34
Motley Fool Wealth Management
Virginia
$3.45M -$103K -3,691 -3%
NI
35
Numeric Investors
Massachusetts
$3.3M +$3.18M +114,184 New
LCM
36
Laurion Capital Management
New York
$2.72M +$2.62M +94,084 New
CC
37
Casdin Capital
New York
$2.6M +$2.51M +90,000 New
AllianceBernstein
38
AllianceBernstein
Tennessee
$2.59M +$810K +29,080 +48%
BIM
39
BlackRock Investment Management
Delaware
$2.53M -$172K -6,190 -7%
Bank of New York Mellon
40
Bank of New York Mellon
New York
$2.49M -$81.5K -2,925 -3%
D.E. Shaw & Co
41
D.E. Shaw & Co
New York
$2.36M +$260K +9,314 +13%
CS
42
Candriam SCA
Luxembourg
$2.29M +$446K +16,000 +25%
GTC
43
Ghost Tree Capital
New York
$2.17M -$3.48M -125,000 -63%
PAM
44
Panagora Asset Management
Massachusetts
$2.11M +$1.67M +59,833 +457%
ACP
45
Acuta Capital Partners
California
$2.08M +$649K +23,300 +48%
BIM
46
Bogle Investment Management
Massachusetts
$2.04M +$1.97M +70,708 New
SI
47
Scout Investments
Missouri
$2.03M
RA
48
Royce & Associates
New York
$1.98M -$557K -20,000 -23%
California Public Employees Retirement System
49
California Public Employees Retirement System
California
$1.96M -$128K -4,600 -6%
SCA
50
Secor Capital Advisors
New York
$1.92M +$241K +8,643 +15%

GHDX Hedge Fund Activity: Q3 2016 in Review

134 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Genomic Health, Inc. (GHDX) for Q3 2016, worth a combined $870M — up 13% from $772M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new GHDX positions and 10 closed out — a net gain of 4 holders — while 53 added to existing stakes and 42 trimmed.

The largest buyer was Columbia Wanger Asset Management, opening a new position worth an estimated $13.1M. The largest seller was Baillie Gifford & Co, cutting an estimated $15.9M.

  • 134 institutional investors held Genomic Health, Inc. (GHDX) as of Q3 2016, up from 130 in Q2 2016.
  • Funds reported $870M of Genomic Health, Inc. stock for Q3 2016, up 13% quarter-over-quarter.
  • 14 funds opened new Genomic Health, Inc. positions in Q3 2016 and 10 closed out, a net change of +4 holders.
  • The largest Genomic Health, Inc. buyer in Q3 2016 was Columbia Wanger Asset Management, an estimated $13.1M added.
  • The largest Genomic Health, Inc. seller in Q3 2016 was Baillie Gifford & Co, an estimated $15.9M sold.

Based on aggregated 13F filings for Q3 2016.